Open AccessOFF-LABEL AND UNLICENSED PRESCRIBING IN PEDIATRIC INPATIENTS WITH NEPHROTIC SYNDROME IN A MAJOR TEACHING HOSPITAL: AN INDONESIAN CONTEXT
Author(s) -
Hesty Utami Ramadaniati,
Taralan Tambunan,
Sondang Khairani,
Happy S Adisty
Publication year - 2016
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017.v10i1.15477
Subject(s) - medicine , nephrotic syndrome , off label use , context (archaeology) , medical prescription , drug , prednisolone , pediatrics , medical record , pharmacology , paleontology , biology
Objective: To estimate the prevalence of off-label and unlicensed prescribing in pediatric inpatients with nephrotic syndrome in a major teachinghospital in Indonesia.Methods: A retrospective study was conducted in study hospital using medical records from pediatric inpatients with nephrotic syndrome during theperiod of January-December 2015. Patient and prescribing data were collected, and drugs were classified as on-label or off-label/unlicensed basedon the Indonesia National Drug Information (IONI). Thereafter, off-label drugs were categorized with a hierarchical system of age, indication, routeof administration, and dosage.Results: There were 1553 drugs with 94 different types of drug administered to 67 patients during the study period. The data uncovered that1023 (65.9%) of the drug prescriptions were used either off-label/unlicensed. Most off-label drugs (n=433, 42.4%) were from nondiureticsantihypertensive drugs. The most common drugs used in an off-label/unlicensed manner were prednisolone and lisinopril. The high rate of off-labeldrug use in children was mainly related to age (n=772, 75.5%). Pediatrics with nephrotic syndrome was vulnerable to off-label uses where everypatient received at least two off-label drugs. It seems that off-label prescribing in pediatric with nephrotic syndrome was not influenced by age orgender as every patient received off-label drugs.Conclusion: Despite the high prevalence of off-label use in pediatric patients with nephrotic syndrome, this use is supported by evidence-basedprescribing. Further, there remains a need for supporting clinical trials for pediatric drugs and updating IONI as the standard drug information inIndonesia to provide complete product information for pediatric use.Keywords: Off-label drug, Syndrome nephrotic, Inpatient, Pediatrics.